The Duke Funding Alert newsletter, published every Monday, provides information on all new and updated grants and fellowships added to the database during the prior week. This listserv is restricted to members of the Duke community.
Cellular Senescence Network: Technology Development and Application (UG3/UH3 Clinical Trial Not Allowed)
The purpose of this Funding Opportunity Announcement is to solicit novel analytics and technologies to identify senescent cells in human tissues This FOA supports the accelerated proof-of-principle demonstration and validation of promising tools, techniques and methods that can be integrated, scaled and applied to multiple human tissues. The initial two-year UG3 phase will support the development and demonstration of feasibility of these emerging technologies in the identification and mapping of senescent cells in mammalian tissues. The subsequent UH3 phase is to support initial validation in human tissues, optimization and scale-up, and generation of production level data. Investigators responding to this FOA must submit both UG3 and UH3 projects as part of a single application. UG3 projects that have met their quantifiable milestones will be administratively considered by NIH staff and prioritized for transition to the UH3 phase, depending on the availability of funds.
Letter of Intent Due Date(s): New Date February 22, 2021
Application Due Date(s): New Date March 22, 2021
RFA-RM-21-009 Expiration Date New Date March 23, 2021 per issuance of NOT-RM-21-014. (Original Expiration Date: March 9, 2021)
An investigator designated as the Contact PD/PI or MPI of an application under this FOA must not be the designated Contact PD/PI of another application under the companion SenNet FOAs RFA-RM-21-008 and RFA-RM-21-009.